CureVac ( ($CVAC) ) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange ...
BioNTech's financial results provide a baseline for the enlarged entity post-CureVac integration. In the third quarter of 2025, the company generated approximately €1.5 billion in revenue and ...
With the merger's completion on January 6, 2026, CureVac's era on the public markets will end. The focus will shift entirely to integrating its clinical candidates, particularly in cancer ...
Following the completion of the share exchange offer in December, BioNTech swiftly moved to acquire the remaining outstanding shares, achieving full integration of CureVac's business operations.
The global respiratory disease vaccine market size was valued at USD 65.72 billion in 2025 and is predicted to hit around USD ...
The multi-month acquisition process has now entered its implementation phase. A central element is the squeeze-out of the remaining minority shareholders. Following the expiration of an additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback